Philip M Potter

List of Publications by Year in Descending Order

93 papers	4,432 citations	40 h-index	64 g-index
95 ext. papers	4,820 ext. citations	6.6 avg, IF	5.08 L-index

#	Paper	IF	Citations
93	Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer. *Cancer Research*, **2020**, 80, 3507-3518	10.1	9
92	Inhibition of carboxylesterase-1 alters clopidogrel metabolism and disposition. *Xenobiotica*, **2020**, 50, 245-251	2	2
91	Clinical genome sequencing uncovers potentially targetable truncations and fusions of MAP3K8 in spitzoid and other melanomas. *Nature Medicine*, **2019**, 25, 597-602	50.5	36
90	Facile synthesis of 1,2-dione-containing abietane analogues for the generation of human carboxylesterase inhibitors. *European Journal of Medicinal Chemistry*, **2018**, 149, 79-89	6.8	15
89	Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. *Bioorganic and Medicinal Chemistry*, **2018**, 26, 25-36	3.4	18
88	Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza ("Danshen"). *Journal of Natural Products*, **2018**, 81, 2410-2418	4.9	3
87	Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping. *Rna*, **2018**, 24, 1056-1066	5.8	18
86	Targeting ALK in pediatric RMS does not induce antitumor activity in vivo. *Cancer Chemotherapy and Pharmacology*, **2018**, 82, 251-263	3.5	5
85	Selective Inhibitors of Human Liver Carboxylesterase Based on a β-Lapachone Scaffold: Novel Reagents for Reaction Profiling. *Journal of Medicinal Chemistry*, **2017**, 60, 1568-1579	8.3	29
84	Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma. *Molecular Therapy - Oncolytics*, **2017**, 4, 67-76	6.4	12
83	Tumour-selective targeting of drug metabolizing enzymes to treat metastatic cancer. *British Journal of Pharmacology*, **2016**, 173, 2811-8	8.6	4
82	Carboxylesterases: General detoxifying enzymes. *Chemico-Biological Interactions*, **2016**, 259, 327-331	5	75
81	Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance. *AAPS Journal*, **2016**, 18, 1391-1405	3.7	59
80	Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates. *Pharmacology Research and Perspectives*, **2015**, 3, e00158	3.1	10
79	Targeting the DNA repair pathway in Ewing sarcoma. *Cell Reports*, **2014**, 9, 829-41	10.6	118
78	Sudemycin E influences alternative splicing and changes chromatin modifications. *Nucleic Acids Research*, **2014**, 42, 4947-61	20.1	50
77	Modulation of esterified drug metabolism by tanshinones from Salvia miltiorrhiza ("Danshen"). *Journal of Natural Products*, **2013**, 76, 36-44	4.9	51

76	Targeting oxidative stress in embryonal rhabdomyosarcoma. *Cancer Cell*, **2013**, 24, 710-24	24.3	182
75	The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. *Drug Discovery Today*, **2013**, 18, 43-9	8.8	81
74	Inhibition of human carboxylesterases hCE1 and hiCE by cholinesterase inhibitors. *Chemico-Biological Interactions*, **2013**, 203, 226-30	5	40
73	Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use. *Stem Cells Translational Medicine*, **2013**, 2, 983-92	6.9	53
72	Control of RhoA methylation by carboxylesterase I. *Journal of Biological Chemistry*, **2013**, 288, 19177-83	5.4	12
71	Toxicology and Biodistribution Studies for MGH2.1, an Oncolytic Virus that Expresses Two Prodrug-activating Genes, in Combination with Prodrugs. *Molecular Therapy - Nucleic Acids*, **2013**, 2, e113	10.7	9
70	Inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by chlorpyrifos oxon, paraoxon and methyl paraoxon. *Toxicology and Applied Pharmacology*, **2012**, 258, 145-50	4.6	40
69	Covalent inhibition of recombinant human carboxylesterase 1 and 2 and monoacylglycerol lipase by the carbamates JZL184 and URB597. *Biochemical Pharmacology*, **2012**, 84, 1215-22	6	25
68	High payload dual therapeutic-imaging nanocarriers for triggered tumor delivery. *Small*, **2012**, 8, 2895-903	13	10
67	Global and local molecular dynamics of a bacterial carboxylesterase provide insight into its catalytic mechanism. *Journal of Molecular Modeling*, **2012**, 18, 2869-83	2	9
66	ATP-dependent mitochondrial porphyrin importer ABCB6 protects against phenylhydrazine toxicity. *Journal of Biological Chemistry*, **2012**, 287, 12679-90	5.4	48
65	Mouse serum paraoxonase-1 lactonase activity is specific for medium-chain length fatty acid lactones. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2011**, 1811, 39-45	5	6
64	Organ-specific carboxylesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. *Biochemical Pharmacology*, **2011**, 81, 24-31	6	67
63	Immobilization of active human carboxylesterase 1 in biomimetic silica nanoparticles. *Biotechnology Progress*, **2011**, 27, 863-9	2.8	10
62	Carboxylesterase inhibitors. *Expert Opinion on Therapeutic Patents*, **2011**, 21, 1159-71	6.8	82
61	Sudemycins, novel small molecule analogues of FR901464, induce alternative gene splicing. *ACS Chemical Biology*, **2011**, 6, 582-9	4.9	132
60	Requirements for mammalian carboxylesterase inhibition by substituted ethane-1,2-diones. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 4635-43	3.4	18
59	Nerve agent hydrolysis activity designed into a human drug metabolism enzyme. *PLoS ONE*, **2011**, 6, e17441	3.7	18

58	In Silico Design and Evaluation of Carboxylesterase Inhibitors. *Journal of Pesticide Sciences*, **2010**, 35, 240-249	2.7	7
57	Human carboxylesterase 1 stereoselectively binds the nerve agent cyclosarin and spontaneously hydrolyzes the nerve agent sarin. *Molecular Pharmacology*, **2010**, 77, 508-16	4.3	43
56	Structure-activity relationships of substituted 1-pyridyl-2-phenyl-1,2-ethanediones: potent, selective carboxylesterase inhibitors. *Journal of Medicinal Chemistry*, **2010**, 53, 8709-15	8.3	15
55	Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2. *Chemical Research in Toxicology*, **2010**, 23, 1890-904	4	70
54	Inhibition of carboxylesterase activity of THP1 monocytes/macrophages and recombinant human carboxylesterase 1 by oxysterols and fatty acids. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2010**, 1801, 31-41	5	34
53	Therapeutic targeting of melanoma cells using neural stem cells expressing carboxylesterase, a CPT-11 activating enzyme. *Current Stem Cell Research and Therapy*, **2010**, 5, 273-6	3.6	22
52	Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis. *Bioorganic and Medicinal Chemistry*, **2009**, 17, 149-64	3.4	32
51	Nanoparticles containing anti-inflammatory agents as chemotherapy adjuvants II: role of plasma esterases in drug release. *AAPS Journal*, **2009**, 11, 120-2	3.7	24
50	Improved, selective, human intestinal carboxylesterase inhibitors designed to modulate 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (Irinotecan; CPT-11) toxicity. *Journal of Medicinal Chemistry*, **2009**, 52, 3742-52	8.3	41
49	Inhibition of carboxylesterase 1 is associated with cholesteryl ester retention in human THP-1 monocyte/macrophages. *Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids*, **2008**, 1781, 643-54	5	64
48	Identification of human intestinal carboxylesterase as the primary enzyme for activation of a doxazolidine carbamate prodrug. *Journal of Medicinal Chemistry*, **2008**, 51, 298-304	8.3	28
47	Evaluation of the Sside doorSin carboxylesterase-mediated catalysis and inhibition. *Biological Chemistry*, **2008**, 389, 149-62	4.5	18
46	Modifications of human carboxylesterase for improved prodrug activation. *Expert Opinion on Drug Metabolism and Toxicology*, **2008**, 4, 1153-65	5.5	25
45	Crystal structures of human carboxylesterase 1 in covalent complexes with the chemical warfare agents soman and tabun. *Biochemistry*, **2007**, 46, 5063-71	3.2	54
44	Selective inhibition of carboxylesterases by isatins, indole-2,3-diones. *Journal of Medicinal Chemistry*, **2007**, 50, 1876-85	8.3	57
43	Planarity and constraint of the carbonyl groups in 1,2-diones are determinants for selective inhibition of human carboxylesterase 1. *Journal of Medicinal Chemistry*, **2007**, 50, 5727-34	8.3	32
42	Analysis of the inhibition of mammalian carboxylesterases by novel fluorobenzoins and fluorobenzils. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 3801-17	3.4	34
41	Hydrolysis of pyrethroids by human and rat tissues: examination of intestinal, liver and serum carboxylesterases. *Toxicology and Applied Pharmacology*, **2007**, 221, 1-12	4.6	155

40	Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma. *Cancer Research*, **2007**, 67, 22-5	10.1	114
39	Analysis of mammalian carboxylesterase inhibition by trifluoromethylketone-containing compounds. *Molecular Pharmacology*, **2007**, 71, 713-23	4.3	37
38	Hydrolytic metabolism of pyrethroids by human and other mammalian carboxylesterases. *Biochemical Pharmacology*, **2006**, 71, 657-69	6	140
37	Development of an etoposide prodrug for dual prodrug-enzyme antitumor therapy. *Molecular Cancer Therapeutics*, **2006**, 5, 1577-84	6.1	7
36	Carboxylesterases--detoxifying enzymes and targets for drug therapy. *Current Medicinal Chemistry*, **2006**, 13, 1045-54	4.3	124
35	Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity. *Molecular Cancer Therapeutics*, **2006**, 5, 2281-8	6.1	37
34	Species differences in the in vitro metabolism of deltamethrin and esfenvalerate: differential oxidative and hydrolytic metabolism by humans and rats. *Drug Metabolism and Disposition*, **2006**, 34, 1764-71	4	86
33	Multisite promiscuity in the processing of endogenous substrates by human carboxylesterase 1. *Journal of Molecular Biology*, **2006**, 363, 201-14	6.5	114
32	Development of a tumor-selective approach to treat metastatic cancer. *PLoS ONE*, **2006**, 1, e23	3.7	100
31	Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan. *Cancer Research*, **2005**, 65, 6850-7	10.1	93
30	Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. *Journal of Molecular Biology*, **2005**, 352, 165-77	6.5	109
29	Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. *Journal of Medicinal Chemistry*, **2005**, 48, 2906-15	8.3	144
28	Inhibition of carboxylesterases by benzil (diphenylethane-1,2-dione) and heterocyclic analogues is dependent upon the aromaticity of the ring and the flexibility of the dione moiety. *Journal of Medicinal Chemistry*, **2005**, 48, 5543-50	8.3	50
27	The crystal structure of the complex of the anticancer prodrug 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) with Torpedo californica acetylcholinesterase provides a molecular explanation for its cholinergic action. *Molecular Pharmacology*, **2005**, 67, 1074-84	4.3	34
26	The 3D structure of the anticancer prodrug CPT-11 with Torpedo californica acetylcholinesterase rationalizes its inhibitory action on AChE and its hydrolysis by butyrylcholinesterase and carboxylesterase. *Chemico-Biological Interactions*, **2005**, 157-158, 153-7	5	11
25	Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11. *Chemico-Biological Interactions*, **2005**, 157-158, 247-52	5	31
24	Mammalian carboxylesterases: from drug targets to protein therapeutics. *Drug Discovery Today*, **2005**, 10, 313-25	8.8	171
23	Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. *Cancer Chemotherapy and Pharmacology*, **2005**, 56, 629-36	3.5	57

22	Development of prodrugs for enzyme-mediated, tumor-selective therapy. *Anti-Cancer Agents in Medicinal Chemistry*, **2005**, 5, 107-13		9
21	Enzyme-prodrug systems: carboxylesterase/CPT-11. *Methods in Molecular Medicine*, **2004**, 90, 247-62		2
20	Molecular modeling of CPT-11 metabolism by carboxylesterases (CEs): use of pnb CE as a model. *Biochemistry*, **2004**, 43, 1874-82	3.2	15
19	Discovery of novel selective inhibitors of human intestinal carboxylesterase for the amelioration of irinotecan-induced diarrhea: synthesis, quantitative structure-activity relationship analysis, and biological activity. *Molecular Pharmacology*, **2004**, 65, 1336-43	4.3	86
18	Characterization of inhibitors of specific carboxylesterases: development of carboxylesterase inhibitors for translational application. *Molecular Cancer Therapeutics*, **2004**, 3, 903-9	6.1	14
17	p53-mediated regulation of expression of a rabbit liver carboxylesterase confers sensitivity to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11). *Journal of Pharmacology and Experimental Therapeutics*, **2003**, 304, 699-705	4.7	1
16	Carboxylesterase-mediated sensitization of human tumor cells to CPT-11 cannot override ABCG2-mediated drug resistance. *Molecular Pharmacology*, **2003**, 64, 279-88	4.3	44
15	Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. *Chemistry and Biology*, **2003**, 10, 341-9		138
14	Synthesis and evaluation of esters and carbamates to identify critical functional groups for esterase-specific metabolism. *Bioorganic and Medicinal Chemistry*, **2003**, 11, 3237-44	3.4	9
13	Structural basis of heroin and cocaine metabolism by a promiscuous human drug-processing enzyme. *Nature Structural and Molecular Biology*, **2003**, 10, 349-56	17.6	170
12	Activation of a camptothecin prodrug by specific carboxylesterases as predicted by quantitative structure-activity relationship and molecular docking studies. *Molecular Cancer Therapeutics*, **2003**, 2, 1171-81	6.1	10
11	Structural insights into CPT-11 activation by mammalian carboxylesterases. *Nature Structural Biology*, **2002**, 9, 337-42		130
10	Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: preclinical assessment and application to bone marrow samples from neuroblastoma patients. *Cancer Research*, **2002**, 62, 5001-7	10.1	20
9	Structural constraints affect the metabolism of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) by carboxylesterases. *Molecular Pharmacology*, **2001**, 60, 355-62	4.3	56
8	Isolation and characterization of a cDNA encoding a horse liver butyrylcholinesterase: evidence for CPT-11 drug activation. *Biochemical Pharmacology*, **2000**, 59, 773-81	6	14
7	Construction of adenovirus for high level expression of small RNAs in mammalian cells. Application to a Bcl-2 ribozyme. *Molecular Biotechnology*, **2000**, 15, 105-14	3	7
6	Comparison of Escherichia coli, Saccharomyces cerevisiae, Pichia pastoris, Spodoptera frugiperda, and COS7 cells for recombinant gene expression. Application to a rabbit liver carboxylesterase. *Molecular Biotechnology*, **2000**, 16, 193-202	3	84
5	Use of the ornithine decarboxylase promoter to achieve N-MYC-mediated overexpression of a rabbit carboxylesterase to sensitize neuroblastoma cells to CPT-11. *Molecular Therapy*, **2000**, 1, 457-63	11.7	8

4	In situ subcellular localization of epitope-tagged human and rabbit carboxylesterases. *Cytometry*, **1998**, 32, 223-232		11
3	Isolation and partial characterisation of a Chinese hamster O6-alkylguanine-DNA alkyltransferase cDNA. *Nucleic Acids Research*, **1992**, 20, 1891-5	20.1	20
2	Tissue-specific expression and induction of human O6-alkylguanine-DNA alkyltransferase in transgenic mice. *Molecular Carcinogenesis*, **1992**, 6, 26-31	5	5
1	Metabolism of 2-naphthylamine and benzidine by rat and human bladder organ cultures. *Carcinogenesis*, **1984**, 5, 949-54	4.6	7